Drug intelligence / Profile preview

FA relaxin

Development stage: Phase 2
Lead developer: Bristol Myers Squibb
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

FA relaxin (BMS-986259) is a novel peptide-based drug developed by Bristol Myers Squibb for the treatment of cardiovascular disorders, primarily acute decompensated heart failure. It acts as a replacement for the endogenous hormone relaxin and functions as an agonist at the Relaxin family peptide receptor 1 (RXFP1) and Relaxin family peptide receptor 2 (RXFP2). The drug is designed to mimic or enhance the effects of natural relaxin, which plays a role in cardiovascular homeostasis and vasodilation. Clinical development has reached Phase 2 trials in patients with acute decompensated heart failure[1][2][4][5].

Other names: BMS-986259BMS986259BMS 986259FA-relaxinFatty acid relaxin

Targets

RXFP1 (Relaxin family peptide receptor 1)RXFP2 (Relaxin family peptide receptor 2)

Beyond the preview

Go deeper on FA relaxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FA relaxin.

Explore the full profile